Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage

Eugene S. Flamm, H. P. Adams, D. W. Beck, R. S. Pinto, J. R. Marler, M. D. Walker, J. C. Godersky, C. M. Loftus, J. Biller, D. J. Boarini, C. O'Dell, K. Banwart, G. Kongable

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

A dose-escalation study of the calcium ion entry blocking drug nicardipine was performed using large dose infusions in 67 patients with recent aneurysmal subarachnoid hemorrhage (SAH). A safe, potentially therapeutic dose of the drug was determined. Patients admitted within 7 days of SAH from a documented cerebral aneurysm were entered into the study if no spasm was present on the initial angiogram. Nicardipine was administered as a continuous intravenous infusion throughout the 14-day period after SAH, regardless of the timing of surgery. To determine the safest possible dose, nicardipine was administerd at seven dose levels from 0.01 to 0.15 mg/kg/hr. The total daily doses ranged from 27.7 mg to 375.0 mg. A follow-up angiogram was carried out on all 67 patients 7 to 10 days after SAH. Computerized tomography and neurological examinations were used to determine the presence of cerebral infarction. No major adverse effects, unexpected reactions, or permanent sequelae could be attributed to nicardipine. A decline in blood pressure was noted following administration of the drug. This occurred more frequently among patients given the largest dose but dit not produce clinical problems or require discontinuation of the drug. Favorable outcomes were noted in 52 patients (78%). Vasospasm was found by arteriography in 31 patients (46%). A dose-related trend was noted: only eight (24%) of 33 patients treated at the highest dose level (approximately 10 mg/hr) developed arteriographic evidence of vasospasm. Symptomatic vasospasm was diagnosed in only two (6%) of 33 patients treated with this dose. Of the 34 patients receiving the lower dose levels, angiographic spasm was observed in 68% and symptomatic vasospasm in 27%. No deaths due to vasospasm occurred. Nicardipine appears to prevent both vasospasm and cerebral ischemia after SAH. A multicenter randomized double-blind trial to test this hypothesis is planned.

Original languageEnglish (US)
Pages (from-to)393-400
Number of pages8
JournalJournal of Neurosurgery
Volume68
Issue number3
StatePublished - 1988
Externally publishedYes

Fingerprint

Nicardipine
Subarachnoid Hemorrhage
Angiography
Spasm
Pharmaceutical Preparations
Cerebral Infarction
Neurologic Examination
Intracranial Aneurysm
Brain Ischemia
Intravenous Infusions
Tomography
Ions
Blood Pressure
Calcium

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Flamm, E. S., Adams, H. P., Beck, D. W., Pinto, R. S., Marler, J. R., Walker, M. D., ... Kongable, G. (1988). Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 68(3), 393-400.

Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. / Flamm, Eugene S.; Adams, H. P.; Beck, D. W.; Pinto, R. S.; Marler, J. R.; Walker, M. D.; Godersky, J. C.; Loftus, C. M.; Biller, J.; Boarini, D. J.; O'Dell, C.; Banwart, K.; Kongable, G.

In: Journal of Neurosurgery, Vol. 68, No. 3, 1988, p. 393-400.

Research output: Contribution to journalArticle

Flamm, ES, Adams, HP, Beck, DW, Pinto, RS, Marler, JR, Walker, MD, Godersky, JC, Loftus, CM, Biller, J, Boarini, DJ, O'Dell, C, Banwart, K & Kongable, G 1988, 'Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage', Journal of Neurosurgery, vol. 68, no. 3, pp. 393-400.
Flamm, Eugene S. ; Adams, H. P. ; Beck, D. W. ; Pinto, R. S. ; Marler, J. R. ; Walker, M. D. ; Godersky, J. C. ; Loftus, C. M. ; Biller, J. ; Boarini, D. J. ; O'Dell, C. ; Banwart, K. ; Kongable, G. / Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. In: Journal of Neurosurgery. 1988 ; Vol. 68, No. 3. pp. 393-400.
@article{ca98058357b645cb973751995358c81a,
title = "Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage",
abstract = "A dose-escalation study of the calcium ion entry blocking drug nicardipine was performed using large dose infusions in 67 patients with recent aneurysmal subarachnoid hemorrhage (SAH). A safe, potentially therapeutic dose of the drug was determined. Patients admitted within 7 days of SAH from a documented cerebral aneurysm were entered into the study if no spasm was present on the initial angiogram. Nicardipine was administered as a continuous intravenous infusion throughout the 14-day period after SAH, regardless of the timing of surgery. To determine the safest possible dose, nicardipine was administerd at seven dose levels from 0.01 to 0.15 mg/kg/hr. The total daily doses ranged from 27.7 mg to 375.0 mg. A follow-up angiogram was carried out on all 67 patients 7 to 10 days after SAH. Computerized tomography and neurological examinations were used to determine the presence of cerebral infarction. No major adverse effects, unexpected reactions, or permanent sequelae could be attributed to nicardipine. A decline in blood pressure was noted following administration of the drug. This occurred more frequently among patients given the largest dose but dit not produce clinical problems or require discontinuation of the drug. Favorable outcomes were noted in 52 patients (78{\%}). Vasospasm was found by arteriography in 31 patients (46{\%}). A dose-related trend was noted: only eight (24{\%}) of 33 patients treated at the highest dose level (approximately 10 mg/hr) developed arteriographic evidence of vasospasm. Symptomatic vasospasm was diagnosed in only two (6{\%}) of 33 patients treated with this dose. Of the 34 patients receiving the lower dose levels, angiographic spasm was observed in 68{\%} and symptomatic vasospasm in 27{\%}. No deaths due to vasospasm occurred. Nicardipine appears to prevent both vasospasm and cerebral ischemia after SAH. A multicenter randomized double-blind trial to test this hypothesis is planned.",
author = "Flamm, {Eugene S.} and Adams, {H. P.} and Beck, {D. W.} and Pinto, {R. S.} and Marler, {J. R.} and Walker, {M. D.} and Godersky, {J. C.} and Loftus, {C. M.} and J. Biller and Boarini, {D. J.} and C. O'Dell and K. Banwart and G. Kongable",
year = "1988",
language = "English (US)",
volume = "68",
pages = "393--400",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage

AU - Flamm, Eugene S.

AU - Adams, H. P.

AU - Beck, D. W.

AU - Pinto, R. S.

AU - Marler, J. R.

AU - Walker, M. D.

AU - Godersky, J. C.

AU - Loftus, C. M.

AU - Biller, J.

AU - Boarini, D. J.

AU - O'Dell, C.

AU - Banwart, K.

AU - Kongable, G.

PY - 1988

Y1 - 1988

N2 - A dose-escalation study of the calcium ion entry blocking drug nicardipine was performed using large dose infusions in 67 patients with recent aneurysmal subarachnoid hemorrhage (SAH). A safe, potentially therapeutic dose of the drug was determined. Patients admitted within 7 days of SAH from a documented cerebral aneurysm were entered into the study if no spasm was present on the initial angiogram. Nicardipine was administered as a continuous intravenous infusion throughout the 14-day period after SAH, regardless of the timing of surgery. To determine the safest possible dose, nicardipine was administerd at seven dose levels from 0.01 to 0.15 mg/kg/hr. The total daily doses ranged from 27.7 mg to 375.0 mg. A follow-up angiogram was carried out on all 67 patients 7 to 10 days after SAH. Computerized tomography and neurological examinations were used to determine the presence of cerebral infarction. No major adverse effects, unexpected reactions, or permanent sequelae could be attributed to nicardipine. A decline in blood pressure was noted following administration of the drug. This occurred more frequently among patients given the largest dose but dit not produce clinical problems or require discontinuation of the drug. Favorable outcomes were noted in 52 patients (78%). Vasospasm was found by arteriography in 31 patients (46%). A dose-related trend was noted: only eight (24%) of 33 patients treated at the highest dose level (approximately 10 mg/hr) developed arteriographic evidence of vasospasm. Symptomatic vasospasm was diagnosed in only two (6%) of 33 patients treated with this dose. Of the 34 patients receiving the lower dose levels, angiographic spasm was observed in 68% and symptomatic vasospasm in 27%. No deaths due to vasospasm occurred. Nicardipine appears to prevent both vasospasm and cerebral ischemia after SAH. A multicenter randomized double-blind trial to test this hypothesis is planned.

AB - A dose-escalation study of the calcium ion entry blocking drug nicardipine was performed using large dose infusions in 67 patients with recent aneurysmal subarachnoid hemorrhage (SAH). A safe, potentially therapeutic dose of the drug was determined. Patients admitted within 7 days of SAH from a documented cerebral aneurysm were entered into the study if no spasm was present on the initial angiogram. Nicardipine was administered as a continuous intravenous infusion throughout the 14-day period after SAH, regardless of the timing of surgery. To determine the safest possible dose, nicardipine was administerd at seven dose levels from 0.01 to 0.15 mg/kg/hr. The total daily doses ranged from 27.7 mg to 375.0 mg. A follow-up angiogram was carried out on all 67 patients 7 to 10 days after SAH. Computerized tomography and neurological examinations were used to determine the presence of cerebral infarction. No major adverse effects, unexpected reactions, or permanent sequelae could be attributed to nicardipine. A decline in blood pressure was noted following administration of the drug. This occurred more frequently among patients given the largest dose but dit not produce clinical problems or require discontinuation of the drug. Favorable outcomes were noted in 52 patients (78%). Vasospasm was found by arteriography in 31 patients (46%). A dose-related trend was noted: only eight (24%) of 33 patients treated at the highest dose level (approximately 10 mg/hr) developed arteriographic evidence of vasospasm. Symptomatic vasospasm was diagnosed in only two (6%) of 33 patients treated with this dose. Of the 34 patients receiving the lower dose levels, angiographic spasm was observed in 68% and symptomatic vasospasm in 27%. No deaths due to vasospasm occurred. Nicardipine appears to prevent both vasospasm and cerebral ischemia after SAH. A multicenter randomized double-blind trial to test this hypothesis is planned.

UR - http://www.scopus.com/inward/record.url?scp=0023848160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023848160&partnerID=8YFLogxK

M3 - Article

C2 - 3343611

AN - SCOPUS:0023848160

VL - 68

SP - 393

EP - 400

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 3

ER -